A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data

MLA

Parneet Cheema, et al. “A Real-World Study of Second or Later-Line Osimertinib in Patients with EGFR T790M-Positive NSCLC: The Final ASTRIS Data.” Future Oncology, vol. 19, Jan. 2023, pp. 61–75. EBSCOhost, https://doi.org/10.2217/fon-2022-0919.

APA

Parneet Cheema, Byoung Chul Cho, Helano Freitas, Mariano Provencio, Yuh Min Chen, Sang-We Kim, Yi-Long Wu, Antonio Passaro, Claudio Martin, Marcello Tiseo, Gee-Chen Chang, Keunchil Park, Benjamin Solomon, Otto Burghuber, Janessa Laskin, Ziping Wang, Sung Yong Lee, Yanping Hu, Johan Vansteenkiste, … Filippo de Marinis. (2023). A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data. Future Oncology, 19, 61–75. https://doi.org/10.2217/fon-2022-0919

Chicago

Parneet Cheema, Byoung Chul Cho, Helano Freitas, Mariano Provencio, Yuh Min Chen, Sang-We Kim, Yi-Long Wu, et al. 2023. “A Real-World Study of Second or Later-Line Osimertinib in Patients with EGFR T790M-Positive NSCLC: The Final ASTRIS Data.” Future Oncology 19 (January): 61–75. doi:10.2217/fon-2022-0919.